Research Papers: Pathology:
Diosmetin exerts anti-oxidative, anti-inflammatory and anti-apoptotic effects to protect against endotoxin-induced acute hepatic failure in mice
Metrics: PDF 1341 views | HTML 1860 views | ?
You Yang1, Xiao-Bao Gong2, Li-Gua Huang2, Zhen-Xu Wang3, Rong-Zhen Wan4, Peng Zhang4, Qing-Yan Zhang4, Zhu Chen3 and Bao-Shun Zhang2
1 College of Animal Science and Technology, Southwest University, Chongqing, P. R. China
2 College of Pharmaceutical Sciences, Southwest University, Chongqing, P. R. China
3 Chongqing Institute for Food and Drug Control, Chongqing, P. R. China
4 The Ninth People’s Hospital of Chongqing, Chongqing, P. R. China
Bao-Shun Zhang, email:
Zhu Chen, email:
Keywords: diosmetin, acute hepatic failure, oxidative stress, inflammatory, apoptosis, Pathology Section
Received: September 18, 2016 Accepted: February 06, 2017 Published: February 16, 2017
To investigate the effects and mechanism of diosmetin on acute hepatic failure (AHF), an AHF murine model was established through administration of lipopolysaccharides/D-galactosamine (LPS/D-GalN). In vitro, diosmetin scavenged free radicals. In vivo, diosmetin decreased mortality among mice, blocked the development of histopathological changes and hepatic damage, and suppressed levels of inflammatory mediators and cytokines. In addition, diosmetin prevented the expression of phosphorylated IKK, IκBα, and NF-κB p65 in the NF-κB signaling pathway, and JNK and p38 in the MAPK signaling pathway. Diosmetin also inhibited hepatocyte apoptosis. Thus, diosmetin exerts protective effects against endotoxin-induced acute hepatic failure in mice. The underlying mechanisms are antioxidation, NF-κB signaling inhibition, inflammatory mediator/cytokine attenuation, and hepatocyte apoptosis suppression. Diosmetin is thus a potential drug candidate for use in the treatment of acute hepatic failure.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.